HMNC Brain Health

HMNC Brain Health is a clinical-stage biopharmaceutical company based in Munich, Germany, focused on developing personalized therapies for mental health disorders, particularly Maj

or Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). Founded in 2010 by Carsten Maschmeyer, the company utilizes a proprietary AI platform that combines psychiatry, genomics, and analytics to create innovative therapies and predictive companion diagnostics. The company is advancing a unique pipeline that includes an oral esketamine formulation as a convenient alternative to existing treatments and a novel therapeutic program targeting TRD. HMNC Brain Health also develops machine learning-enabled companion diagnostics and patented genetic tests to enhance patient stratification and treatment outcomes. With a commitment to improving the quality of life for patients who have not responded to traditional treatments, HMNC Brain Health aims to deliver targeted solutions that address various neuropsychiatric conditions, including stress, sleep disorders, and ADHD.